High Vitamin D (25-OH-D Above 100 ng/mL): When It Is Toxicity and When It Is Just a High Result

Laboratories report 25-OH-D in ng/mL or in nmol/L — and with a 'high' result it is worth checking the unit first. The conversion: the concentration in nmol/L is approximately the concentration in ng/mL multiplied by 2.5 (so 40 ng/mL ≈ 100 nmol/L, 100 ng/mL ≈ 250 nmol/L). A unit mix-up can 'produce' an alarmingly high result, for example 100 nmol/L is in fact only 40 ng/mL.

Note that different societies adopt different upper limits of a 'safe' concentration and different therapeutic targets. The 2023 Polish guidelines give 30–50 ng/mL as the target range; the 2011 Institute of Medicine report concluded that 20 ng/mL covers the needs of most of the population and pointed to a 'U-shaped' curve — risk at both very low and very high values. The Endocrine Society in its 2024 guideline states that there is no evidence allowing the optimal 25-OH-D level for disease prevention to be defined. So there is no single universal threshold above which anyone is automatically poisoned.

Vitamin D in the body is a hormone: cholecalciferol from a supplement is hydroxylated in the liver to 25-OH-D (the storage form, and the one measured in the test), and then in the kidneys to 1,25-dihydroxyvitamin D (calcitriol) — the active form. Calcitriol increases calcium absorption from the gut and, together with PTH, enhances calcium release from bone. Normally the amount of calcitriol is tightly regulated: when there is enough calcium, PTH falls and renal calcitriol production decreases, and the enzyme CYP24A1 inactivates the excess metabolites.

With very large doses this braking system stops being sufficient. High 25-OH-D concentrations displace and saturate the vitamin D-binding protein, the free fraction and biological action on gut and bone rise, and as a result calcium in blood and urine increases while PTH is suppressed. The typical laboratory picture of poisoning is: high calcium, low or low-normal PTH, high 25-OH-D, and increased urinary calcium excretion (hypercalciuria). Hypercalciuria can be an earlier signal than hypercalcaemia itself — and it is on this that the European Food Safety Authority based its assessment of the tolerable upper intake.

Symptoms of hypercalcaemia are non-specific and increase with the calcium level: thirst and frequent urination, nausea, loss of appetite, constipation, abdominal pain, weakness, irritability, poor concentration, and at high values confusion, heart rhythm disturbances and kidney failure. Chronically raised calcium favours kidney stones and kidney calcification. We write more broadly about hypercalcaemia itself, its causes and work-up in a separate article on high blood calcium.

This study is valuable because it shows the picture from real practice rather than from isolated clinical cases: a high 25-OH-D result became more common (along with the fashion for supplementation and for testing this vitamin), but acute toxicity remained rare. Of the 37 people with a value of at least 100 ng/mL, the great majority had no complication at all. The practical conclusion is twofold: on one hand a high result is no reason for panic, on the other — the fact that toxicity is rare does not mean it never happens, or that calcium does not need checking.

True vitamin D toxicity is described in the literature as rare and usually related to doses many times above those recommended. In a 2011 report, two people took for a longer time supplements that, because of manufacturing and labelling errors, contained more than 1000 times more vitamin D3 than the recommended daily dose implied. Both developed severe hypercalcaemia proportional to the 25-OH-D concentration (but not to 1,25-dihydroxyvitamin D); calcium normalised and symptoms resolved only after 25-OH-D fell below about 400 ng/mL, and normalisation of 25-OH-D itself took about a year.

These two reports illustrate a key point: real poisonings involve concentrations several times higher than the 100 ng/mL line and usually originate in a manufacturer's error or in doses in the hundreds of thousands of units per day, not in regular supplementation of 2000–4000 IU. So if someone taking a reasonable dose gets a very high result (several hundred ng/mL), it is worth considering laboratory error, a unit mix-up or a faulty product — and telling the doctor. The authors of both papers stress that patients must be asked repeatedly about supplements, because people often do not regard them as potentially harmful.

Not everyone tolerates vitamin D equally. A case has been described of a 58-year-old woman who, after 8000 IU a day (tapered to 2000 IU over three months) despite being vitamin D replete at baseline, developed hypercalcaemia and kidney stones. Tests showed high calcium, low PTH, high 25-OH-D and high 1,25-dihydroxyvitamin D, and also low 24,25-dihydroxyvitamin D, suggesting loss of function of the CYP24A1 enzyme responsible for breaking down active metabolites. The authors stress that in such people even moderate doses can lead to toxicity and that calcium should be monitored in anyone being supplemented.

This is of course a single case report, but it illustrates a mechanism that clinicians regard as real: genetic or acquired impairment of vitamin D degradation increases sensitivity. Other situations associated with a higher risk of hypercalcaemia on supplementation include granulomatous diseases (for example sarcoidosis), in which the tissues themselves produce calcitriol, hyperparathyroidism, some cancers, and also medicines that reduce urinary calcium excretion (for example thiazide diuretics) or additional high doses of calcium preparations. People with a history of kidney stones should discuss vitamin D supplementation with a doctor.

With a 25-OH-D result above 100 ng/mL, the typical medical plan is simple. First, establishing what was taken and at what dose, and a break in supplementation until it is clarified. Second, measurement of calcium (total, preferably with albumin, or ionised) and PTH. Third, assessment of the kidneys (creatinine, eGFR) and, if calcium is raised or there are symptoms, urinary calcium. If calcium is normal, PTH is not raised, and the 25-OH-D result is within the high double digits to low hundreds ng/mL, a break in supplementation and a check after a few weeks is usually enough.

When calcium is clearly raised, treatment involves stopping vitamin D and calcium preparations, hydration (often intravenous), and in severe cases medicines that help lower calcium, as in the series of children described above. Treatment is carried out under medical supervision; 'flushing out' vitamin D on your own with a lot of water is neither effective nor safe in hypercalcaemia. Normalisation of 25-OH-D takes a long time — from a few weeks to a year — because calcidiol has a long half-life in the body and is stored in fat tissue.

The European Food Safety Authority (EFSA) in its 2023 opinion set the tolerable upper intake level (UL) for vitamin D at 100 µg (4000 IU) a day for adults, including pregnant and lactating women, and adolescents aged 11–17, and at 50 µg (2000 IU) for children aged 1–10. Persistent hypercalciuria was chosen as the critical endpoint, and a LOAEL of 250 µg/day was identified from two randomised trials, with an uncertainty factor of 2.5 applied. EFSA notes that European populations are unlikely to exceed the UL, except for regular users of supplements with high doses of vitamin D.

For comparison, to our knowledge the 2011 Endocrine Society guideline allowed higher doses (up to 10,000 IU a day as the upper limit in adults in the context of treating deficiency), whereas the 2011 IOM report and EFSA adopt a limit of 4000 IU a day. In its newer 2024 guideline the Endocrine Society advises against routine supplementation above DRI levels in healthy adults under 75 and against routine 25-OH-D testing without indications. These are differences of context — treatment of a diagnosed deficiency versus prevention — not a contradiction; what matters is not to confuse therapeutic doses used under medical supervision with preventive doses taken 'on your own initiative'.

Groups that should talk to a doctor before supplementing with larger doses deserve separate mention: people with sarcoidosis and other granulomatous diseases, with hyperparathyroidism, with a history of kidney stones, with kidney disease, taking thiazide diuretics or calcium supplements. In them even an 'ordinary' dose may require a calcium check after a few weeks.

To sum up: a high vitamin D is a result that should neither be dismissed nor dramatised. A value above 100 ng/mL requires checking the unit, the list of preparations taken, calcium and PTH — and most often ends in a break in supplementation and follow-up. Real poisonings are rare and involve extreme doses or faulty products, but precisely because they are rare, they are easy to miss if nobody asks about supplements.